<DOC>
	<DOCNO>NCT00039338</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy drug surgery may shrink tumor remove surgery . Radiation therapy use high-energy x-ray kill tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . It yet know whether chemotherapy effective follow surgery combine radiation therapy treat cervical cancer . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy follow radical hysterectomy chemotherapy plus radiation therapy treat patient stage IB stage II cervical cancer .</brief_summary>
	<brief_title>Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy Patients With Stage IB II Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall progression-free survival patient stage IB2 , IIA , IIB cervical cancer treat neoadjuvant cisplatin-based chemotherapy follow radical hysterectomy vs standard therapy comprise concurrent radiotherapy cisplatin-based chemotherapy . - Compare toxicity regimens patient . - Compare quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , FIGO stage , age ( 18 50 v 51 75 ) , histological subtype ( adenomatous v non-adenomatous component ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive neoadjuvant cisplatin-based chemotherapy day 1 . Treatment repeat every 21 day . Within 6 week last chemotherapy course , patient undergo type III-V Piver-Rutledge radical hysterectomy . Patients positive lymph node tumor invasion parametria le 5 mm resection border surgery receive standard adjuvant external beam radiotherapy daily , 5 day week , 5-5.6 week ( 25-28 treatment day ) follow external boost radiotherapy brachytherapy 1 2 day . - Arm II : Patients receive standard therapy comprise radiotherapy arm I concurrently cisplatin-based chemotherapy weekly 6 week . Adjuvant hysterectomy allow , recommend , case histologically proven residual tumor . Treatment arm continue absence disease progression unacceptable toxicity . For patient arm , cisplatin may combine chemotherapeutics long minimum platinum dose give . Quality life assess baseline 6 , 12 , 18 , 24 month . Patients follow every 3 month 1 year , every 6 month 4 year , annually thereafter . PROJECTED ACCRUAL : A total 686 patient ( 343 per treatment arm ) accrue study within 3.8 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cervical cancer , include follow subtypes : Squamous cell carcinoma Adenosquamous cell carcinoma Adenocarcinoma ( exclude small cell , clear cell , rare variant classical adenocarcinoma ) FIGO stage IB2 , IIA ( great 4 cm ) , IIB PATIENT CHARACTERISTICS : Age : 18 75 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 1.46 mg/dL Renal : Creatinine clearance great 60 mL/min Other : No prior concurrent malignancy except adequately treat basal cell skin cancer No psychological , familial , sociological , geographical condition would preclude study Not pregnant PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify Other : No concurrent anticancer agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>